Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2006 2
2007 3
2008 3
2009 1
2010 3
2011 4
2012 3
2013 4
2014 6
2015 2
2016 3
2017 7
2018 8
2019 4
2020 6
2021 9
2022 3
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results.
Assan O, Memoli V, Guillaumie L, Turcotte V, Lemay M, Dionne A, Lemieux J, Provencher L, Gotay C, de Bruin M, Guénette L, Lauzier S. Assan O, et al. Among authors: lemieux j. J Cancer Surviv. 2024 May 4. doi: 10.1007/s11764-024-01599-y. Online ahead of print. J Cancer Surviv. 2024. PMID: 38702555
A Single-Center 18-Year Series of 73 Cases of Metaplastic Carcinoma of the Breast.
Thériault K, Ben Moussa M, Perron M, Desbiens C, Poirier B, Poirier É, Leblanc D, Morin C, Lemieux J, Hogue JC, Boudreau D. Thériault K, et al. Among authors: lemieux j. Breast J. 2024 Jan 4;2024:5920505. doi: 10.1155/2024/5920505. eCollection 2024. Breast J. 2024. PMID: 38223556 Free PMC article.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Balmaña J, et al. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. Goodwin PJ, et al. Among authors: lemieux j. J Clin Oncol. 2023 Dec 10;41(35):5356-5362. doi: 10.1200/JCO.23.00296. Epub 2023 Sep 11. J Clin Oncol. 2023. PMID: 37695982 Free PMC article. Clinical Trial.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Schmid P, Cortes J, Joaquim A, Jañez NM, Morales S, Díaz-Redondo T, Blau S, Neven P, Lemieux J, García-Sáenz JÁ, Hart L, Biyukov T, Baktash N, Massey D, Burris HA 3rd, Rugo HS. Schmid P, et al. Among authors: lemieux j. Breast Cancer Res. 2023 Jun 12;25(1):67. doi: 10.1186/s13058-023-01649-w. Breast Cancer Res. 2023. PMID: 37308971 Free PMC article. Clinical Trial.
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32).
Hershman DL, Chen BE, Sathe C, Parulekar WR, Lemieux J, Ligibel JA, Gelmon KA, Whelan TJ, Goodwin PJ. Hershman DL, et al. Among authors: lemieux j. Breast Cancer Res Treat. 2023 Jul;200(1):93-102. doi: 10.1007/s10549-023-06922-2. Epub 2023 May 9. Breast Cancer Res Treat. 2023. PMID: 37157006 Clinical Trial.
Adherence to CONSORT Guidelines and Reporting of the Determinants of External Validity in Clinical Oncology Randomized Controlled Trials: A Review of Trials Published in Four Major Journals between 2013 and 2015.
Audet S, Doyle C, Lemieux C, Tardif MA, Gauvreau A, Simonyan D, Nabi H, Lemieux J. Audet S, et al. Among authors: lemieux j. Curr Oncol. 2023 Feb 8;30(2):2061-2072. doi: 10.3390/curroncol30020160. Curr Oncol. 2023. PMID: 36826121 Free PMC article. Review.
Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial.
Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho GY, Popescu BA, Kosmala W, Costello B, la Gerche A, Mottram P, Thomas L, Seldrum S, Hristova K, Bansal M, Kurosawa K, Fukuda N, Yamada H, Izumo M, Tajiri K, Sinski M, Vinereanu D, Shkolnik E, Banchs J, Kutty S, Negishi K, Marwick TH. Negishi T, et al. Among authors: lemieux j. JACC Cardiovasc Imaging. 2023 Mar;16(3):269-278. doi: 10.1016/j.jcmg.2022.10.010. Epub 2022 Nov 16. JACC Cardiovasc Imaging. 2023. PMID: 36435732 Free article. Clinical Trial.
70 results